Investor Relations

Neurodegenerative and neuropsychiatric disease, multi-billion dollar markets, unmet need, decades of research de-risk our drugs

Lucid-MS: New Chemical Entity for Multiple Sclerosis, pre-clinical research re-established use of paralyzed rear legs in MS mouse model, research published in peer-reviewed journals. Quantum BioPharma has finished dosing in phase-1 for Lucid-MS (Lucid-21-302) for first in-class human safety and tolerability investigation

IP Estate: Quantum BioPharma has rights to patent families licensed on an exclusive basis

Quantum BioPharma’s flagship subsidiary led by Dr. Lakshmi Kotra, the recipient of the Julia Levy Award and a senior scientist at the Krembil Brain Institute, as well as the world-renowned University Health Network (UHN).

Quantum BioPharma has a world class team working full-time on pipeline development, with backgrounds at the FDA, major pharmaceuticals firms, and esteemed universities.

Quantum BioPharma team includes Julia recipient, a distinguished award that has only been awarded to 8 recipients since its inception in 2005 (no other company can make this claim)

Cash enough to carry operations

Only 73,259,688 million shares issued

• 6 Class A shares 
• 1,300,727 Class B shares
• 48,951 Options
• 138,077 Warrants

Share repurchase plan completed for 2022, approximately 2 million shares returned to treasury in 2022. Another 2 million shares returned to treasury in 2023.

Co-founders, directors and other insiders frequently buying shares since start of 2022 and continue to accumulate shares. This can be verified by checking the SEDI filings.